<?xml version='1.0' encoding='utf-8'?>
<document id="28599060"><sentence text="Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension."><entity charOffset="75-85" id="DDI-PubMed.28599060.s1.e0" text="Sacubitril" /><entity charOffset="86-95" id="DDI-PubMed.28599060.s1.e1" text="Valsartan" /><entity charOffset="97-103" id="DDI-PubMed.28599060.s1.e2" text="LCZ696" /><entity charOffset="109-119" id="DDI-PubMed.28599060.s1.e3" text="Sildenafil" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e0" e2="DDI-PubMed.28599060.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e0" e2="DDI-PubMed.28599060.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e0" e2="DDI-PubMed.28599060.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e0" e2="DDI-PubMed.28599060.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e1" e2="DDI-PubMed.28599060.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e1" e2="DDI-PubMed.28599060.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e1" e2="DDI-PubMed.28599060.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e2" e2="DDI-PubMed.28599060.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s1.e2" e2="DDI-PubMed.28599060.s1.e3" /></sentence><sentence text="Sacubitril/valsartan (LCZ696) is indicated for the treatment of patients with heart failure and reduced ejection fraction (HFrEF)"><entity charOffset="0-10" id="DDI-PubMed.28599060.s2.e0" text="Sacubitril" /><entity charOffset="11-20" id="DDI-PubMed.28599060.s2.e1" text="valsartan" /><entity charOffset="22-28" id="DDI-PubMed.28599060.s2.e2" text="LCZ696" /><pair ddi="false" e1="DDI-PubMed.28599060.s2.e0" e2="DDI-PubMed.28599060.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28599060.s2.e0" e2="DDI-PubMed.28599060.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s2.e0" e2="DDI-PubMed.28599060.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s2.e1" e2="DDI-PubMed.28599060.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s2.e1" e2="DDI-PubMed.28599060.s2.e2" /></sentence><sentence text=" Since patients with HFrEF may receive sacubitril/valsartan and sildenafil, both increasing cyclic guanosine monophosphate, the present study evaluated the pharmacokinetic and pharmacodynamic drug interaction potential between sacubitril/valsartan and sildenafil"><entity charOffset="39-49" id="DDI-PubMed.28599060.s3.e0" text="sacubitril" /><entity charOffset="50-59" id="DDI-PubMed.28599060.s3.e1" text="valsartan" /><entity charOffset="64-74" id="DDI-PubMed.28599060.s3.e2" text="sildenafil" /><entity charOffset="92-122" id="DDI-PubMed.28599060.s3.e3" text="cyclic guanosine monophosphate" /><entity charOffset="227-237" id="DDI-PubMed.28599060.s3.e4" text="sacubitril" /><entity charOffset="238-247" id="DDI-PubMed.28599060.s3.e5" text="valsartan" /><entity charOffset="252-262" id="DDI-PubMed.28599060.s3.e6" text="sildenafil" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e0" e2="DDI-PubMed.28599060.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e0" e2="DDI-PubMed.28599060.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e0" e2="DDI-PubMed.28599060.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e0" e2="DDI-PubMed.28599060.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e0" e2="DDI-PubMed.28599060.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e0" e2="DDI-PubMed.28599060.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e0" e2="DDI-PubMed.28599060.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e1" e2="DDI-PubMed.28599060.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e1" e2="DDI-PubMed.28599060.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e1" e2="DDI-PubMed.28599060.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e1" e2="DDI-PubMed.28599060.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e1" e2="DDI-PubMed.28599060.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e1" e2="DDI-PubMed.28599060.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e2" e2="DDI-PubMed.28599060.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e2" e2="DDI-PubMed.28599060.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e2" e2="DDI-PubMed.28599060.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e2" e2="DDI-PubMed.28599060.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e2" e2="DDI-PubMed.28599060.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e3" e2="DDI-PubMed.28599060.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e3" e2="DDI-PubMed.28599060.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e3" e2="DDI-PubMed.28599060.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e3" e2="DDI-PubMed.28599060.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e4" e2="DDI-PubMed.28599060.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e4" e2="DDI-PubMed.28599060.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e4" e2="DDI-PubMed.28599060.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e5" e2="DDI-PubMed.28599060.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s3.e5" e2="DDI-PubMed.28599060.s3.e6" /></sentence><sentence text=" In this open-label, three-period, single sequence study, patients with mild-to-moderate hypertension (153" /><sentence text="8 Â± 8" /><sentence text="2 mmHg mean systolic blood pressure (SBP)) received a single dose of sildenafil 50 mg, sacubitril/valsartan 400 mg once daily for 5 days, and sacubitril/valsartan and sildenafil coadministration"><entity charOffset="69-79" id="DDI-PubMed.28599060.s6.e0" text="sildenafil" /><entity charOffset="87-97" id="DDI-PubMed.28599060.s6.e1" text="sacubitril" /><entity charOffset="98-107" id="DDI-PubMed.28599060.s6.e2" text="valsartan" /><entity charOffset="142-152" id="DDI-PubMed.28599060.s6.e3" text="sacubitril" /><entity charOffset="153-162" id="DDI-PubMed.28599060.s6.e4" text="valsartan" /><entity charOffset="167-177" id="DDI-PubMed.28599060.s6.e5" text="sildenafil" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e0" e2="DDI-PubMed.28599060.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e0" e2="DDI-PubMed.28599060.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e0" e2="DDI-PubMed.28599060.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e0" e2="DDI-PubMed.28599060.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e0" e2="DDI-PubMed.28599060.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e0" e2="DDI-PubMed.28599060.s6.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e1" e2="DDI-PubMed.28599060.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e1" e2="DDI-PubMed.28599060.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e1" e2="DDI-PubMed.28599060.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e1" e2="DDI-PubMed.28599060.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e1" e2="DDI-PubMed.28599060.s6.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e2" e2="DDI-PubMed.28599060.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e2" e2="DDI-PubMed.28599060.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e2" e2="DDI-PubMed.28599060.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e2" e2="DDI-PubMed.28599060.s6.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e3" e2="DDI-PubMed.28599060.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e3" e2="DDI-PubMed.28599060.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e3" e2="DDI-PubMed.28599060.s6.e5" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e4" e2="DDI-PubMed.28599060.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s6.e4" e2="DDI-PubMed.28599060.s6.e5" /></sentence><sentence text=" When coadministered with sildenafil, the AUC and Cmax of valsartan decreased by 29% and 39%, respectively"><entity charOffset="26-36" id="DDI-PubMed.28599060.s7.e0" text="sildenafil" /><entity charOffset="58-67" id="DDI-PubMed.28599060.s7.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.28599060.s7.e0" e2="DDI-PubMed.28599060.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28599060.s7.e0" e2="DDI-PubMed.28599060.s7.e1" /></sentence><sentence text=" Coadministration of sacubitril/valsartan and sildenafil resulted in a greater decrease in BP (-5/-4/-4 mmHg mean ambulatory SBP/DBP/MAP (mean arterial pressure)) than with sacubitril/valsartan alone"><entity charOffset="21-31" id="DDI-PubMed.28599060.s8.e0" text="sacubitril" /><entity charOffset="32-41" id="DDI-PubMed.28599060.s8.e1" text="valsartan" /><entity charOffset="46-56" id="DDI-PubMed.28599060.s8.e2" text="sildenafil" /><entity charOffset="173-183" id="DDI-PubMed.28599060.s8.e3" text="sacubitril" /><entity charOffset="184-193" id="DDI-PubMed.28599060.s8.e4" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e0" e2="DDI-PubMed.28599060.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e0" e2="DDI-PubMed.28599060.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e0" e2="DDI-PubMed.28599060.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e0" e2="DDI-PubMed.28599060.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e0" e2="DDI-PubMed.28599060.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e1" e2="DDI-PubMed.28599060.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e1" e2="DDI-PubMed.28599060.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e1" e2="DDI-PubMed.28599060.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e1" e2="DDI-PubMed.28599060.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e2" e2="DDI-PubMed.28599060.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e2" e2="DDI-PubMed.28599060.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e2" e2="DDI-PubMed.28599060.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e3" e2="DDI-PubMed.28599060.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28599060.s8.e3" e2="DDI-PubMed.28599060.s8.e4" /></sentence><sentence text=" Both treatments were generally safe and well tolerated in this study; however, the additional BP reduction suggests that sildenafil should be administered cautiously in patients receiving sacubitril/valsartan"><entity charOffset="122-132" id="DDI-PubMed.28599060.s9.e0" text="sildenafil" /><entity charOffset="189-199" id="DDI-PubMed.28599060.s9.e1" text="sacubitril" /><entity charOffset="200-209" id="DDI-PubMed.28599060.s9.e2" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.28599060.s9.e0" e2="DDI-PubMed.28599060.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28599060.s9.e0" e2="DDI-PubMed.28599060.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s9.e0" e2="DDI-PubMed.28599060.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28599060.s9.e1" e2="DDI-PubMed.28599060.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28599060.s9.e1" e2="DDI-PubMed.28599060.s9.e2" /></sentence><sentence text=" Unique identifier: NCT01601470" /><sentence text="" /></document>